脑室内注射瘦素对大鼠迷走复合体瘦素受体表达的影响
摘要
目的探讨脑室内注射瘦素后大鼠迷走复合体瘦素受体(Ob-R)表达的变化。方法将SD大鼠24只随机分为对照组和瘦素干预1 h组(A组)、3 h组(B组)、5 h组(C组),每组6只。给药前1周行侧脑室置管,置管1周后无麻醉状态下对照组侧脑室注射生理盐水,A、B、C组侧脑室注射瘦素,剂量均为3.5μg/μL。实验结束后取脑组织,用HE染色进行迷走复合体定位,用免疫组化方法测定Ob-R在迷走复合体的表达。结果 A、B、C组Ob-R阳性细胞数分别为(12.49±1.66)、(12.54±2.16)、(12.89±1.86)个,对照组阳性细胞数为(5.66±1.04)个;A、B、C组Ob-R阳性细胞光密度积分分别为(28.41±3.60)、(26.18±6.17)、(24.56±4.14)分,对照组为(16.02±2.06)分;与对照组比较,A、B、C组Ob-R阳性细胞数、阳性细胞光密度积分增多(P均<0.05)。A、B、C三组间Ob-R阳性细胞数、阳性细胞光密度积分比较差异无统计学意义(P均>0.05)。结论瘦素中枢干预后可刺激迷走复合体上Ob-R的表达上调,瘦素刺激时间与Ob-R水平无关。
引文
[1]Park HK,Ahima RS.Physiology of leptin:energy homeostasis,neuroendocrine function and metabolism[J].Metabolism,2015,64(1):24-34.
[2]Dalamaga M,Chou SH,Shields K,et al.Leptin at the intersection of neuroendocrinology and metabolism:current evidence and therapeutic perspectives[J].Cell Metab,2013,18(1):29-42
[3]Moon HS,Dalamaga M,Kim SY,et al.Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals[J].Endocr Rev,2013,34(3):377-412.
[4]Hausman GJ,Barb CR,Lents CA.Letin and reproductive function[J].Biochimie,2012,94(10):2075-2081.
[5]Alix PM,Guebre-Egziabher F,Soulage CO.Leptin as an uremic toxin:Deleterious role of in chronic kidney disease[J].Biochimie,2014,105(10):12-21.
[6]Upadhyay J,Farr OM,Mantzoros CS.The role of leptin in regulating bone metabolism[J].Metabolism,2015,64(1):105-113.
[7]van Swieten MM,Pandit R,Adan RA,et al.The neuroanatomical function of leptin in the hypothalamus[J].J Chem Neuroanat,2014,61-62(11):207-220.
[8]Fujimiya M,Inui A.Peptidergic regulation of gastrointestinal motility in rodents[J].Peptides,2000,21(10):1565-1582.
[9]Schaab M,Kratzsch J.The soluble leptin receptor[J].Best Pract Res Clin Endocrinol Metab,2015,29(5):661-670.
[10]Travagli RA,Rogers RC.Receptors and transmission in the braingut axis:potential for novel therapies[J].Am J Physiol Gastrointest Liver Physiol,2001,281(3):G595-601.
[11]Lewis MW,Hermann GE,Rogers RC,et al.In vitro and in vivo analysis of the effects of corticotropin releasing factor on rat dorsal vagal complex[J].J Physiol,2002,543(Pt 1):135-146.
[12]Buhmann H,le Roux CW,Bueter M.The gut-brain axis in obesity[J].Best Pract Res Clin Gastroenterol,2014,28(4):559-571
[2]Dalamaga M,Chou SH,Shields K,et al.Leptin at the intersection of neuroendocrinology and metabolism:current evidence and therapeutic perspectives[J].Cell Metab,2013,18(1):29-42
[3]Moon HS,Dalamaga M,Kim SY,et al.Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals[J].Endocr Rev,2013,34(3):377-412.
[4]Hausman GJ,Barb CR,Lents CA.Letin and reproductive function[J].Biochimie,2012,94(10):2075-2081.
[5]Alix PM,Guebre-Egziabher F,Soulage CO.Leptin as an uremic toxin:Deleterious role of in chronic kidney disease[J].Biochimie,2014,105(10):12-21.
[6]Upadhyay J,Farr OM,Mantzoros CS.The role of leptin in regulating bone metabolism[J].Metabolism,2015,64(1):105-113.
[7]van Swieten MM,Pandit R,Adan RA,et al.The neuroanatomical function of leptin in the hypothalamus[J].J Chem Neuroanat,2014,61-62(11):207-220.
[8]Fujimiya M,Inui A.Peptidergic regulation of gastrointestinal motility in rodents[J].Peptides,2000,21(10):1565-1582.
[9]Schaab M,Kratzsch J.The soluble leptin receptor[J].Best Pract Res Clin Endocrinol Metab,2015,29(5):661-670.
[10]Travagli RA,Rogers RC.Receptors and transmission in the braingut axis:potential for novel therapies[J].Am J Physiol Gastrointest Liver Physiol,2001,281(3):G595-601.
[11]Lewis MW,Hermann GE,Rogers RC,et al.In vitro and in vivo analysis of the effects of corticotropin releasing factor on rat dorsal vagal complex[J].J Physiol,2002,543(Pt 1):135-146.
[12]Buhmann H,le Roux CW,Bueter M.The gut-brain axis in obesity[J].Best Pract Res Clin Gastroenterol,2014,28(4):559-571